• English
    • العربية
  • العربية
  • Login
  • QU
  • QU Library
  •  Home
  • Communities & Collections
  • Help
    • Item Submission
    • Publisher policies
    • User guides
    • FAQs
  • About QSpace
    • Vision & Mission
View Item 
  •   Qatar University Digital Hub
  • Qatar University Institutional Repository
  • Academic
  • Faculty Contributions
  • College of Health Sciences
  • Public Health
  • View Item
  • Qatar University Digital Hub
  • Qatar University Institutional Repository
  • Academic
  • Faculty Contributions
  • College of Health Sciences
  • Public Health
  • View Item
  •      
  •  
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar

    Thumbnail
    View/Open
    Publisher version (You have accessOpen AccessIcon)
    Publisher version (Check access options)
    Check access options
    1-s2.0-S1201971222005227-main.pdf (569.2Kb)
    Date
    2022-11
    Author
    Ahmed, Zaqout
    Almaslamani, Muna A.
    Chemaitelly, Hiam
    Hashim, Samar A.
    Ittaman, Ajithkumar
    Alimam, Abeir
    Rustom, Fatma
    Daghfal, Joanne
    Abukhattab, Mohammed
    AlMukdad, Sawsan
    Kaleeckal, Anvar Hassan
    Latif, Ali Nizar
    Butt, Adeel A.
    Bertollini, Roberto
    Al-Khal, Abdullatif
    Omrani, Ali S.
    Abu-Raddad, Laith J.
    ...show more authors ...show less authors
    Metadata
    Show full item record
    Abstract
    ObjectivesTo estimate the real-world effectiveness of sotrovimab against severe, critical, or fatal COVID-19 in Qatar at a time in which most SARS-CoV-2 incidences occurred due to the BA.2 Omicron subvariant. MethodsWe conducted a matched case-control study among all individuals eligible for sotrovimab treatment per United States Food and Drug Administration guidelines in the resident population of Qatar. The odds of progression to severe forms of COVID-19 were compared in cases (treatment group) versus controls (eligible patients who opted not to receive the treatment). Subgroup analyses were conducted. ResultsA total of 3364 individuals were eligible for sotrovimab treatment during the study period, of whom 519 individuals received the treatment, whereas the remaining 2845 constituted the controls. The adjusted odds ratio of disease progression to severe, critical, or fatal COVID-19 comparing the treatment group to the control group was 2.67 (95% confidence interval 0.60-11.91). In the analysis including only the subgroup of patients at higher risk of severe forms of COVID-19, the adjusted odds ratio was 0.65 (95% confidence interval 0.17-2.48). ConclusionThere was no evidence for a protective effect of sotrovimab in reducing COVID-19 severity in a setting dominated by the BA.2 subvariant.
    URI
    https://www.sciencedirect.com/science/article/pii/S1201971222005227
    DOI/handle
    http://dx.doi.org/10.1016/j.ijid.2022.09.023
    http://hdl.handle.net/10576/45351
    Collections
    • COVID-19 Research [‎848‎ items ]
    • Medicine Research [‎1739‎ items ]
    • Public Health [‎480‎ items ]

    entitlement


    Qatar University Digital Hub is a digital collection operated and maintained by the Qatar University Library and supported by the ITS department

    Contact Us | Send Feedback
    Contact Us | Send Feedback | QU

     

     

    Home

    Submit your QU affiliated work

    Browse

    All of Digital Hub
      Communities & Collections Publication Date Author Title Subject Type Language Publisher
    This Collection
      Publication Date Author Title Subject Type Language Publisher

    My Account

    Login

    Statistics

    View Usage Statistics

    About QSpace

    Vision & Mission

    Help

    Item Submission Publisher policiesUser guides FAQs

    Qatar University Digital Hub is a digital collection operated and maintained by the Qatar University Library and supported by the ITS department

    Contact Us | Send Feedback
    Contact Us | Send Feedback | QU

     

     

    Video